Safinamide:(S)-(+)-2-[4-(3-Fluorobenzyloxy)Benzylamino]Propanamide Methansulfonate

Safinamide, which is (S) - (+) -2- [4- (3-fluorobenzyloxy) benzylamino] propionamide methanesulfonate, has the following mechanism of action.
This drug is mainly used in the treatment of Parkinson's disease. The mechanism is the inhibition of monoamine oxidase-B (MAO-B). MAO-B is widely present in the brain and degrades dopamine, which is a key neurotransmitter in Parkinson's disease. When Safinamide inhibits MAO-B, the pathway of dopamine degradation is blocked, resulting in an increase in dopamine levels in the brain, just like adding water to a fountain of exhaustion, filling it with water, thereby improving symptoms such as motor retardation and tremor caused by dopamine deficiency in Parkinson's disease patients.
Secondly, Safinamide can also regulate the voltage-gated sodium ion channel. This channel plays an important role in the transmission of nerve impulses. When nerve cells are excited, sodium ions flow through this channel. Safinamide regulates it, which can make the discharge pattern of nerve cells more stable and prevent nerve cell overexcitation. Like traffic control, it allows the transmission of nerve impulses to proceed in an orderly manner, prevents the disturbance and excessive issuance of signals, thereby reducing the symptoms of Parkinson's disease patients, and can reduce the risk of abnormal dopamine release due to excessive excitation of nerve cells.
Furthermore, Safinamide may regulate glutaminergic neurotransmission. Glutamate is an important excitatory neurotransmitter in the brain. During the pathogenesis of Parkinson's disease, the glutaminergic system is unbalanced, and excessive release of glutamate may cause cell nerve damage. Safinamide can regulate this system to normalize the release of glutamate, such as steering, restoring balance to nerve transmission, reducing nerve cell damage, and achieving the purpose of treating Parkinson's disease.

Safinamide, namely (S) - (+) -2- [4- (3-fluorobenzyloxy) benzylamino] propanamide methanesulfonate, has many advantages in the treatment of Parkinson's disease.
First, the mechanism of action is unique. It not only inhibits monoamine oxidase B, reduces dopamine degradation, and increases dopamine levels, but also regulates voltage-gated sodium channels and regulates neurotransmitter release. This multi-action pathway is like a carefully laid out array, which improves the symptoms of Parkinson's disease in an all-round way, and is comparable to drugs without a single mechanism of action.
Second, the curative effect is accurate. Many clinical trials have shown that it can effectively reduce the "off" period time of Parkinson's disease patients, prolong the "on" period and do not cause dyskinesia. It is like a good doctor in improving symptoms such as motor retardation, tremor, and myotonia, and significantly improves patients' motor function and quality of life.
Third, the safety is very good. The drug has relatively mild and low incidence of adverse reactions, and most patients can tolerate it well. Compared with other Parkinson's disease treatment drugs, it is like a stable boat. On the road of treatment, it rarely causes serious adverse reactions such as orthostatic hypotension and hallucinations, escorting the treatment journey.
Fourth, it is convenient to take. It only needs to be taken once a day, which greatly improves the patient's medication compliance, just like intimate guidelines, making it easier for patients to follow the treatment plan, ensuring the continuity and stability of treatment, and facilitating the long-term treatment of Parkinson's disease.

There are 600 kinds of medicines in "Thunder Gong Cannon Pharmaceutical Solution", which are divided into gold and stone, grass, wood, fruit, grain, vegetables, humans, animals, poultry, insects and fish, etc., on their nature and taste, main treatment, fear of evil, and repair. Although I don't know what you said about "Safinamide: (S) - (+) -2- [4- (3-Fluorobenzyloxy) Benzylamino] Propanamide Methansulfonate" in ancient texts, but in today's medical view, its adverse reactions really need to be studied in detail.
It may be caused by gastrointestinal discomfort, such as nausea, vomiting, and diarrhea. This is because the medicine enters the spleen and stomach, disturbing its ability to transport and transform. Those with the spleen and stomach are the officials of the warehouse, and the five flavors come out. The nature of medicine is fierce, and the spleen and stomach are difficult to adapt, so the transportation and transformation are abnormal, and the water and valley do not melt, resulting in nausea, vomiting, and diarrhea.
Or cause changes in the nervous system, such as headache, dizziness, and insomnia. The brain is the sea of marrow, the meeting of all yang. Medicine enters the meridians, the movement of qi and blood is disturbed, the clear yang does not rise, the turbid yin does not fall, and the brain orifices are disnourished, so headache and dizziness. And the heart dominates the gods, and when you are at peace, you sleep. Medicine disturbs the mind and the mind, and the mind is not at home, so it causes insomnia.
Furthermore, there may be differences in the blood system, such as thrombocytopenia. Blood, the subtle transformation of water and valley, the heart dominates blood, The bias of the medicine, injures the heart and spleen, the spleen does not control blood, the heart does not control blood, and the platelet production or metabolism is abnormal, which is the appearance of thrombocytopenia.
Or there is an allergy, skin rash, itching. The lungs are the main skin, the poison of the medicine invades the lungs, the lungs are lost, the guards are discordant, and the skin is depressed, so it occurs as a red rash and itching.
Anyone who uses the medicine should carefully examine its symptoms, identify its causes, and weigh the pros and cons to prevent the survival of adverse reactions and achieve the effect of treating the disease and saving people.

Safinamide, or (S) - (+) -2- [4- (3-fluorobenzyloxy) benzylamino] propionamide methanesulfonate, is recommended at a dose that varies depending on a variety of factors.
In the treatment of Parkinson's disease, the starting dose is usually 50 mg once a day. As the treatment progresses, the dose can be cautiously increased to 100 mg once a day depending on the patient's individual tolerance and clinical efficacy. It should be noted that this dose adjustment should be carried out under close supervision of the doctor.
Dose adjustment is also critical if the patient has liver and kidney insufficiency. Patients with mild hepatic insufficiency may not need to adjust the dose significantly; patients with moderate and severe hepatic insufficiency need to be particularly cautious and may need to reduce the dose. Patients with renal insufficiency should also make appropriate adjustments to the dose according to the degree of renal damage.
When actually taking medication, the doctor will comprehensively consider the patient's age, weight, overall health status, and the interaction between other drugs being taken. Therefore, patients must strictly follow the doctor's instructions and do not increase or decrease the dose by themselves to ensure the safety and efficacy of the medication.

Zalfenamide, which is (S) - (+) -2- [4- (3-fluorobenzyloxy) benzylamino] propionamide methanesulfonate, interacts with other drugs in the treatment of Parkinson's disease.
If used together with dopamine receptor agonists, both act on the dopamine system or increase the dopaminergic effect, causing adverse reactions such as nausea, vomiting, hypotension, and dyskinesia. However, moderate dosage can synergistically improve Parkinson's symptoms, such as motor retardation and tremor.
When monoamine oxidase-B inhibitors are used in combination with them, because the two have an impact on the metabolism of monoamine neurotransmitters, the combined use may cause excessive increase in the level of dopamine and other transmitters in the brain, causing severe adverse reactions such as hypertensive crisis, hot topic, and psychiatric symptoms. Therefore, combined use requires extreme caution and close monitoring of patients' signs and symptoms.
When catechol-O-methyltransferase inhibitors are used in combination with sufenamide, they can affect the metabolic process of the drug in the body, or change the blood concentration of sufenamide, which in turn affects the efficacy and safety. Clinical combination requires fine adjustment of the drug dose according to the specific reaction of the patient.
Anticholinergic drugs and sulfenamide are taken together, although they may relieve some symptoms of Parkinson's disease or have a synergistic effect, but the combination of the two may aggravate anticholinergic adverse reactions such as dry mouth, constipation, difficulty urinating, and blurred vision. When using, it is necessary to weigh the advantages and disadvantages and pay close attention to the patient's tolerance.